OBJECTIVE: To study the cell effects of raloxifene on uterine and leiomyoma tissue in postmenopausal women. DESIGN: Prospective, randomized, double-blind, placebo-controlled study. SETTING: Department of Obstetrics and Gynecology, University "Magna Graecia" of Catanzaro, Italy. PATIENT(S): Forty postmenopausal women affected by uterine leiomyomas and selected for hysterectomy. INTERVENTION(S): Treatment for three cycles of 28 days with raloxifene at a dose of 180 mg/day orally (raloxifene group) or placebo tablets (3 tablets/day orally) (placebo group). MAIN OUTCOME MEASURE(S): Uterine and leiomyoma dimensions were measured in each subject at entry and before surgery. On leiomyomas and homologous myometrium the proliferating cell nuclear antigen (PCNA)-positive cells/total cells (PCNA/TC) and the Bcl-2-positive cells/Bax-positive cells (Bcl-2/Bax) ratios (%), as proliferation and apoptotic indexes, respectively, were measured. RESULT(S): After treatment, uterine and leiomyoma sizes were significantly changed in comparison with baseline and the placebo group. PCNA/TC and Bcl-2/Bax ratios were significantly higher in leiomyomas than in homologous myometrium. A significant difference was detected in PCNA/TC between the myometrium of the raloxifene and control groups, whereas no difference was observed in the Bcl-2/Bax ratio. A significant difference in PCNA/TC and Bcl-2/Bax ratios was detected in leiomyoma tissue between the raloxifene group and controls. CONCLUSION(S): In postmenopausal women, raloxifene administration reduces uterine leiomyomas by exerting a cell antiproliferative and proapoptotic action.
RCT Entities:
OBJECTIVE: To study the cell effects of raloxifene on uterine and leiomyoma tissue in postmenopausal women. DESIGN: Prospective, randomized, double-blind, placebo-controlled study. SETTING: Department of Obstetrics and Gynecology, University "Magna Graecia" of Catanzaro, Italy. PATIENT(S): Forty postmenopausal women affected by uterine leiomyomas and selected for hysterectomy. INTERVENTION(S): Treatment for three cycles of 28 days with raloxifene at a dose of 180 mg/day orally (raloxifene group) or placebo tablets (3 tablets/day orally) (placebo group). MAIN OUTCOME MEASURE(S): Uterine and leiomyoma dimensions were measured in each subject at entry and before surgery. On leiomyomas and homologous myometrium the proliferating cell nuclear antigen (PCNA)-positive cells/total cells (PCNA/TC) and the Bcl-2-positive cells/Bax-positive cells (Bcl-2/Bax) ratios (%), as proliferation and apoptotic indexes, respectively, were measured. RESULT(S): After treatment, uterine and leiomyoma sizes were significantly changed in comparison with baseline and the placebo group. PCNA/TC and Bcl-2/Bax ratios were significantly higher in leiomyomas than in homologous myometrium. A significant difference was detected in PCNA/TC between the myometrium of the raloxifene and control groups, whereas no difference was observed in the Bcl-2/Bax ratio. A significant difference in PCNA/TC and Bcl-2/Bax ratios was detected in leiomyoma tissue between the raloxifene group and controls. CONCLUSION(S): In postmenopausal women, raloxifene administration reduces uterine leiomyomas by exerting a cell antiproliferative and proapoptotic action.
Authors: Nancy H Collins; Elizabeth C Lessey; Carolyn D DuSell; Donald P McDonnell; Lindsay Fowler; Wilder A Palomino; Maria J Illera; Xianzhong Yu; Bilan Mo; Angela M Houwing; Bruce A Lessey Journal: Biol Reprod Date: 2008-10-15 Impact factor: 4.285
Authors: Erin I Lewis; Rebecca J Chason; Alan H DeCherney; Alicia Armstrong; John Elkas; Aradhana M Venkatesan Journal: Fertil Steril Date: 2013-03-05 Impact factor: 7.329
Authors: Elizabeth A Pritts; David J Vanness; Jonathan S Berek; William Parker; Ronald Feinberg; Jacqueline Feinberg; David L Olive Journal: Gynecol Surg Date: 2015-05-19